Gefitinib is a novel targeted therapeutic agent that acts as a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor gene (EGFR) sensitive mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.